3Grillo-Lopez AJ, Cheson BD, Homing SJ, et al. Response criteria for NHL:importance of 'normal' lymph node size and correlations with re- sponse rates[J]. Ann Oncol,2000,11 (4) :399-408.
4McLaughlin P, Grillo-Lopeza J, Link BK, et al. Rituxmab chimeric anti- CD20 monoclonal antibody therapy fo relapsed indolent lymphoma:half of patients respond to a four-dose treatment program [ J ]. J Clin Oncol, 1998 , 16 ( 8 ) : 2825-33.
5Coiftier B, Haioun C, Ketrerer N, et al. Rituximab ( anti-CD20 mono- clonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase Ⅱ study[J]. Blood,1998,92 (6) :1927-32.
6Park BB, Kim WS, Eom HS, et al. Salvage therapy with gemcitabine, ifos- famide,dexamethasone,and oxaliplatin(GIDOX) for B-cell non Hodgkin' s lymphoma: a consortium for improving survival of lymphoma (CISL) trial[ J]. Invest New Drugs ,2011 ,29 (1) :154-60.
7Messori A,Vaiani M,Trippoli S,et al.Survival in patients with intermediate or high grade non-Hodgkin's lymphoma metaanalysis of randomized studies comparing third generation regimen with CHOP[J].Br J Cancer,2001,84:303-307.
8Buzzoni R,Coueom M,Neui P,et al.Results of a slvage regimen in refractory or relapsed non-Hodgkin's lymphoma[J].Leuk Lymphoma,1994,14(1):121-128.
9Philip T,Guglielmi C,Hagenbeek A,et al.Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma[J].N Engl J Med,1995,333(13):1540-1545.
